At the forefront of hematology and hemato-oncology, we provide innovative treatments and compassionate care, advancing patient outcomes and setting new standards in the diagnosis and management of blood disorders.
About Dr. Karthik Rengaraj
Dr. Karthik Rengaraj is a highly esteemed Hematology Consultant with a distinguished career dedicated to the diagnosis and treatment of blood disorders. His journey into hematology was profoundly influenced by personal experience: in 2009, his aunt, Mrs. Alli Palanivelu, was diagnosed with high-risk Myelodysplastic Syndrome (MDS). Witnessing her health challenges, struggles with diagnosis, and treatment inspired Dr. Karthik to specialize in hematology. Her passing left a deep impression on him, fueling his commitment to alleviating the physical, mental, and financial burdens of patients suffering from blood disorders.
With over a decade of experience in the field, Dr. Karthik has earned a reputation for his expertise, compassionate care, and dedication to improving patient outcomes for people from all walks of life.
Our specialized team of hematology and hemato-oncology professionals brings extensive experience and advanced expertise to every patient.
Each patient receives tailored care plans designed to address their unique needs and conditions, enhancing outcomes and overall well-being.
We prioritize empathy and support, offering a patient-centered approach that respects individual needs and provides.
Recognized with prestigious awards and memberships, our institution is dedicated to maintaining high standards and achieving excellence in hematology.
Acute Leukemias are aggressive cancers of the blood and bone marrow, characterized by rapid cell proliferation. Treatment involves intensive chemotherapy, targeted therapy, and possibly stem cell transplantation for better outcomes.
Chronic Leukemias are cancers of the blood and bone marrow that progress more slowly. Management often includes targeted therapy, medications, and monitoring, aiming to control the disease and improve quality of life.
Myelodysplastic Syndrome (MDS) is a group of disorders caused by poorly formed or dysfunctional blood cells. Treatment focuses on improving blood cell production through medications, blood transfusions.
To lead in hematology and hemato-oncology, advancing treatment and research while providing compassionate, patient-centered care in resource-limited settings.
Deliver expert, accessible care, drive innovation, and enhance patient outcomes through dedication and cutting-edge practices.
Excellence, integrity, innovation, compassion, and collaboration guide our commitment to exceptional patient care and scientific advancement.
